Navigation Links
Results of the RIFLE STEACS clinical trial reported at TCT 2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 Results of a randomized clinical trial suggest that using the transradial approach for angioplasty in patients with ST elevation acute coronary syndrome is preferable to the femoral approach, and should be the recommended access route.

Results of the Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome (RIFLE STEACS) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Bleeding complications in patients with acute coronary syndrome (ACS) are a significant predictor of mortality and recent data suggest that in these patients, the radial approach could be associated with improved mortality and morbidity.

Researchers in this trial sought to determine whether transradial access for ST elevation Acute Coronary Syndrome (STEACS) treatment is associated with better outcomes when compared to transfemoral approach

The study was a prospective, randomized, parallel group, multi-center trial. Before arterial stick for percutaneous access, all STEACS patients eligible for acute revascularization were randomized (1:1 ratio) to radial or femoral access. 1,001 STEMI patients were enrolled between January 2009 and July 2011 in four high-volume clinical sites in Italy.

The primary endpoint of the study was the rate at 30 days of net adverse clinical events (NACE), a composite of cardiac death, myocardial infarction, stroke, target lesion revascularization or non-coronary artery bypass graft (non-CABG)-related major bleeding. Secondary endpoints were individual components of NACE.

At 30 days, the rate of NACE was significantly lower in the radial group when compared to the femoral group, 13.6% vs. 21.0% respectively. This difference was determined by a reduction of both the major adverse cardiac and cerebrovascular events (MACCE), 7.2% vs. 11.4%, and of bleeding, 7.8% vs. 12.2%. In particular, the rate of cardiac death at 30 days was 9.2% in the femoral group and 5.2% in the radial group.

"Radial access in patients with ST elevation acute coronary syndrome is associated with significant clinical benefits, in terms of both lower morbidity and mortality," said Enrico Romagnoli, MD, PhD, a member of the Interventional Cardiology Unit at Policlinico Casilino in Rome, Italy.

"The radial approach should no longer just be considered a valid alternative to the femoral one, but become the recommended access site for ST elevation acute coronary syndrome," concluded Dr. Romagnoli.


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
2. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
3. Combination epigenetic therapy clinical trial results
4. Results of the PARIS registry Reported at TCT 2011
5. Results of the TRIGGER-PCI trial reported at TCT 2011
6. Results of rapid gene trial reported at TCT 2011
7. Results of the BRIDGE trial reported at TCT 2011
8. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
9. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
10. E-counselling shows dramatic results in lowering blood pressure
11. Less Frequent Mammograms May Lower False-Positive Results
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: